Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
|Technology Name |
(St. Jude Reference #)
|Acute Megakaryoblastic Leukemia (AMKL) Fusion Genes (SJ-01-0001)|
|Description||Researchers at St. Jude Children's Research Hospital and the Hospital for Sick Children identified the t(1;22)(p13;q13) translocation whose resulting fusion genes, RBM15 and MKL1, are associated with acute megakaryoblastic leukemia (AMKL). The nucleotide sequence encoding the RBM-15/MLK fusion protein provides a useful diagnostic assay for identifying this leukemia. Other aspects of this invention are methods for identifying agents capable of binding to the fusion protein and for identifying agents useful for treating patients with AMKL.|
|Keywords||Acute Megakaryoblastic Leukemia, AMKL; fusion gene; translocation|
|Granted Patents or Published Applications||U.S. Patent No. 7,329,744|
|Related Scientific References|| |
Ma et al., “Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia”, Nature Genetics 28(3): 220-221 (2001)
Cen B. Selvaraj, et al. "Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes." Mol Cell Biol. 2003 Sep:23(18):6597-608.
|Licensing Opportunities||We are currently seeking licensing opportunities in all fields for the development of this technology.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: September 2008